About
Activities

Please donate

Please support us
with your donation
Donate here

Member Area
Search
Member Login

Some areas of this website are accessible to registered members only.


If you have no account yet, please click on "Register". If you have forgotten your password, please click on "Forgot login?".

Members Online
None
You are here: Home Virtual Education Program Susan Branford - The importance of BCR-ABL kinase domain mutation analysis in CML

The importance of BCR-ABL kinase domain mutation analysis in CML

Susan Branford, University of Adelaide, Australia

Please wait some seconds before the educational presentation will start below. You can also click on the slides to jump to certain sections of the presentation. Please share your feedback below, and see the other Virtual Education Program modules.

Issues covered

  • Mutations as a mechanism of imatinib resistance
  • Why mutations arise
  • When to test for mutations
  • Therapeutic options in the presence of mutations

Has this been helpful? Please provide your comments here:

Facteur de variabilité de la réponse au ITK</li>
              <li>Les trois grand mécanismes de résistance</li>
              <li>La réponse au traitement</li>
              <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib

 5000 Characters left

Antispam Refresh image Case sensitive

© iCMLf International Chronic Myeloid Leukemia Foundation